Cited by 158Cancer Cells and MetastasisTGF-β signaling in diseasesMechanisms of cancer metastasis

Epithelial–mesenchymal-transition-inducing transcription factors: new targets for tackling chemoresistance in cancer?

van Staalduinen, Jente, Baker, David, ten Dijke, Peter, van Dam, Hans·2018·Oncogene

Abstract

Chemoresistance remains a major complication of cancer treatments. Recent data provide strong evidence that chemoresistance is linked to epithelial-mesenchymal transition (EMT), a latent developmental process, which is re-activated during cancer progression. EMT involves transcriptional reprogramming and is driven by specific EMT transcription factors (EMT-TFs). In this review, we provide support for the idea that EMT-TFs contribute to the development of resistance against cancer therapy and discuss how EMT-TFs might be targeted to advance novel therapeutic approaches to the treatment of cancer.

Integrity signals

Registry

Crossref · 10.1038/s41388-018-0378-x

Cites

205 of 205 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Carcinoma cells undergoing EMT tend to be more resistant to chemotherapy.

    “EMT also correlates with increased resistance of carcinoma cells to chemotherapies149–152.”

    From TGFβ biology in cancer progression and immunotherapy (2021) · cites this paper as [150]

Cites

2 retracted

Flagged first, then by citations

Cited by

Sorted by citations

Authors
van Staalduinen, J., Baker, D., ten Dijke, P., & van Dam, H.
Affiliations
Leiden University Medical Center (NL)
Venue
Oncogene
Published
2018-07-12
Volume
37
Issue
48
Pages
6195-6211
ISSN
  • 0950-9232 (ISSN-L)
  • 1476-5594
OpenAlex
W2870937227
Cited by
158
References
205
Citations by year
2026: 6 · 2025: 9 · 2024: 13 · 2023: 18 · 2022: 30 · 2021: 27 · 2020: 32 · 2019: 22 · 2018: 1
FWCI
2.15
Type
journal article
Language
en
Open access
closed
Locations
  • Oncogene (publishedVersion)
  • PubMed (publishedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • Leiden Repository (Leiden University) (submittedVersion)
Funders
Cancer Genomics Centre
Topics
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mechanisms of cancer metastasis
Keywords
epithelial-mesenchymal transition, EMT transcription factors, chemoresistance, cancer therapy resistance, transcriptional reprogramming, targeted cancer therapy, tumor progression
MeSH terms
Animals, Humans, Neoplasms, Transcription Factors, Drug Resistance, Neoplasm, Epithelial-Mesenchymal Transition

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review